Obesity and the Risk of Low Bicarbonate: A Cohort Study
Douglas C. Lambert and Matthew K. Abramowitz

Rationale & Objective: Acid retention may occur in the absence of overt metabolic acidosis; thus it is important to identify populations at risk. Because obesity may alter renal acid-base handling, we sought to determine whether overweight and obesity are associated with increased risk for low serum bicarbonate levels, suggesting metabolic acidosis.

Study Design: Retrospective cohort study.

Setting & Participants: Adult patients (n = 96,147) visiting outpatient clinics in the Bronx, NY, between January 1, 2010, and December 31, 2015.

Predictor: Body mass index (BMI).

Outcome: Low serum bicarbonate level (≤23 mEq/L).

Analytical Approach: Longitudinal analyses were conducted using mixed-effects models to examine associations of BMI with serum bicarbonate levels over time and Cox proportional hazards models to examine associations of BMI with incident low bicarbonate levels.

Results: During a median follow-up of 4.4 (interquartile range, 2.3-6.3) years, patients had a median of 8 serum bicarbonate measurements and 34,539 patients developed low bicarbonate levels. Higher BMI was associated with progressively lower serum bicarbonate levels, with attenuation of the association in the highest BMI groups, suggesting a J-shaped relationship. Compared with the reference group (BMI, 18.5 to <25 kg/m²), patients with BMIs of 25 to <30, 30 to <35, 35 to <40, and ≥40 kg/m² had HRs for incident low bicarbonate levels of 1.10 (95% CI, 1.05-1.14), 1.16 (95% CI, 1.11-1.21), 1.20 (95% CI, 1.14-1.26), and 1.15 (95% CI, 1.09-1.22). Results were similar after adjustment for serum urea nitrogen level and exclusion of patients with diabetes, hypertension, or estimated glomerular filtration rates < 60 mL/min/1.73 m².

Limitations: Arterial pH measurements were unavailable.

Conclusions: Higher BMI is independently associated with progressively greater risk for developing low serum bicarbonate levels, indicating likely metabolic acidosis. Further research should explore the causes of low bicarbonate levels in patients with overweight and obesity.

Metabolic acidosis is a common complication of chronic kidney disease (CKD) that is implicated in higher rates of skeletal muscle protein breakdown, muscle weakness, functional limitation, and bone disease. Population studies of adults with and without CKD reveal that metabolic acidosis, defined by a low serum bicarbonate level, is also associated with increased risk for kidney function decline and all-cause mortality. Randomized trials have shown that treatment of metabolic acidosis in patients with CKD slows kidney functional decline and improves physical functioning.

Adverse clinical consequences have been linked to acid-base changes even in the absence of overt metabolic acidosis. Lower serum bicarbonate levels within the normal range are associated with kidney function decline, in addition to low cardiorespiratory fitness, diabetes, and low bone mineral density. Furthermore, alkali treatment of patients with CKD without metabolic acidosis reduces levels of markers of kidney damage and slows glomerular filtration rate (GFR) decline, whereas in adults without CKD who do not have overt metabolic acidosis, alkali treatment reduces levels of markers of muscle and bone loss and preserves bone mineral density. Therefore, treatment of acid-mediated organ damage may be indicated before metabolic acidosis is evident. Thus, it is important to identify populations at risk for this process.

Intriguing data suggest that one such risk factor may be obesity. In cross-sectional analyses, greater waist circumference has been associated with lower serum bicarbonate levels in patients with CKD, and greater body mass index (BMI) has been associated with lower serum bicarbonate levels in patients without CKD. Additionally, higher BMI is associated with lower urinary pH, higher net acid excretion, and lower urinary citrate excretion. Therefore, obesity and its associated metabolic consequences may predispose patients to metabolic acid-base disturbances, and these may be detectable before the development of overt metabolic acidosis.

However, to date, the relationship of BMI with acid-base status has been examined to only a limited extent. Given the independent risk for CKD associated with obesity and metabolic syndrome, it is important to clarify the extent to which obesity predisposes patients to developing low bicarbonate levels. This information may suggest appropriate clinical interventions to reduce the already high burden of disease among overweight and obese individuals.

We hypothesized that higher BMI would be associated with lower serum bicarbonate levels and increased risk for
Overweight and obesity are risk factors for chronic kidney disease (CKD) and have been associated with lower urinary pH, suggesting possible abnormalities in acid-base status. It has not been determined whether obesity is associated with developing low serum bicarbonate levels, an indicator of acid-base abnormality and a risk factor for CKD. We analyzed a large cohort of patients using an observational study design to determine whether greater body mass index (BMI) is associated with greater risk for developing low serum bicarbonate levels. Our results showed that greater BMI is associated with progressively greater risk for developing low serum bicarbonate levels. These findings reveal a potentially treatable abnormality to help prevent CKD and other morbidity in those with overweight and obesity.

METHODS

Study Population
We assembled a cohort of patients who visited outpatient clinics within the Montefiore Medical Center (MMC) health system between January 1, 2010, and December 31, 2015. Inclusion criteria were age 18 years or older, complete demographic data, 2 or more outpatient clinic visits during the study period with a basic metabolic panel checked within 24 hours of the visit, and BMI or weight value recorded at the office visit or within 90 days before or after each visit. The index date was defined as the first basic metabolic panel date. The index BMI was calculated as the average of BMI values obtained during the 90 days before and after the index date. To ensure adequate collection of comorbid condition data, all patients were additionally required to have been seen in an MMC clinic within 1 year before the index date.

Patients were excluded if they had, within 10 years before or 90 days after the index date, any International Classification of Diseases, Ninth Revision (ICD-9) diagnosis code for a kidney transplant, congestive heart failure, pulmonary hypertension, asthma, chronic obstructive pulmonary disease or other diffuse parenchymal lung disease, obesity hypoventilation syndrome or obstructive sleep apnea syndrome, hyperaldosteronism, inflammatory bowel disease or chronic diarrhea, ascites, cirrhosis, liver disease, connective tissue disease, HIV infection, AIDS, or any malignancy or if they had filled within 90 days before or after the index date any outpatient prescription for diuretics, sodium citrate, sodium bicarbonate, potassium chloride, or antiretroviral medications. Patients with baseline bicarbonate levels < 15 or > 40 mEq/L or baseline BMI < 15 or > 60 kg/m² were excluded as outliers (n = 636). The final cohort consisted of 96,147 patients (Fig 1).

The study was approved by the Institutional Review Board for MMC/Albert Einstein College of Medicine (Institutional Review Board number: 2018-9100). The need for informed consent was waived due to the use of deidentified data.

Data Collection
Age, sex, race/ethnicity, insurance status, zip codes, comorbid medical conditions, and laboratory data were obtained from the electronic health record of MMC. Available body metric and laboratory data for each patient were collected from the index date through July 1, 2018. BMI was calculated as weight in kilograms divided by height in meters squared. BMI values > 10 kg/m² higher or lower than those temporally adjacent for a given patient were excluded as erroneous. Patients who identified as Black Hispanic were included as Hispanic. Patients who identified as Asian were pooled with patients who did not identify as Black, Hispanic, or White because of the small sample size.

Baseline diabetes was defined by any occurrence within 5 years before or 90 days after the index date, an ICD-9 code related to type 2 diabetes, hemoglobin A1c value ≥ 6.5%, or any prescription for diabetes medications. Baseline hypertension and coronary artery disease were defined by ICD-9 codes within 5 years before or 90 days after the index date. Income was defined as the median income.
within each patient’s home zip code using the 2013 to 2017 American Community 5-year estimates from the Census Bureau. To qualify for inclusion, laboratory data had to have been collected within 24 hours of the index date and any subsequent office visits. Data were excluded if additional basic metabolic panels occurred within 7 days after this so as to avoid inclusion of probable hospital or emergency department blood samples or those drawn during acute illness or medication changes in the outpatient setting. Incident low bicarbonate level was defined as the presence of at least 2 bicarbonate values ≤ 23 mEq/L after the index date; time to incident low bicarbonate level was defined by the date of the first of these.

All outpatient blood samples were processed centrally at the same MMC hospital laboratory and analyzed using a standardized process. Samples were drawn by venipuncture and delivered immediately to the laboratory or refrigerated at 4 to 8 °C until analyzed. Serum creatinine was measured using a modified kinetic Jaffé reaction, and bicarbonate levels, by a phosphoenolpyruvate carboxylase method on the Hitachi Modular System (Roche Diagnostics). Estimated GFR (eGFR) was calculated using the 4-variable CKD Epidemiology Collaboration (CKI-EPI) formula. Statistical Analyses

Patients were stratified by 6 categories of BMI based on World Health Organization classifications. Baseline characteristics by BMI category were analyzed using analysis of variance for continuous variables and χ² tests for categorical variables. Linear regression models were created to examine baseline associations of BMI with serum bicarbonate levels. Effect modification was examined between BMI and key covariates by including multiplicative interaction terms in the models. The association of BMI with serum bicarbonate levels over time was examined using mixed-effects models specifying random intercepts to account for within-person correlation and incorporating time-updated eGFR, BMI, and serum bicarbonate values. Values for BMI and bicarbonate were averaged over every 6-month period to facilitate the use of data from visits in which only BMI or only bicarbonate was measured. The risk for incident low bicarbonate levels by BMI category among patients who did not have low bicarbonate levels at baseline was examined using Cox proportional hazards models. Time zero was the date of the first serum bicarbonate value. Patients were censored at the last available bicarbonate value. The proportional hazards assumption was verified by visual inspection of log-log plots.

For all models, covariates selected a priori as potential confounders included age, sex, race/ethnicity, eGFR, income, insurance status, baseline hypertension, baseline diabetes, and baseline coronary artery disease. The continuous association of BMI with risk for incident low bicarbonate levels was also examined by creating a restricted cubic spline model. P < 0.05 was considered statistically significant. All analyses were performed using Stata, version 13.1 (StataCorp).

Sensitivity Analyses

To account for the effects of dietary protein, we included serum urea nitrogen (SUN) level in additional linear regression and Cox proportional hazards model analyses. To determine whether our findings were driven by participants with CKD, we analyzed a subgroup comprising patients with eGFRs ≥ 60 mL/min/1.73 m² and by additional eGFR subgroups. In light of the significant influence of angiotensin-converting enzyme inhibitors on bicarbonate levels, we analyzed a subgroup of patients without hypertension at baseline. To test the robustness of our definition of incident low bicarbonate level, we conducted a second analysis in which 2 bicarbonate levels ≤ 23 mEq/L were required with an interval of 365 days or less between them.

RESULTS

Baseline Characteristics

Mean age of the study population was 50.3 ± 17 years, with 61,864 (64%) women, 34,335 (36%) Hispanic, 32,700 (34%) Black, and 11,044 (12%) White participants (Table 1). Most patients were overweight (BMI, 25–<30 kg/m²), followed by obese class 1 (BMI, 30–<35 kg/m²), and normal weight (BMI, 18–24.9 kg/m²). Higher BMI was associated with a greater prevalence of hypertension, diabetes, and coronary artery disease (Table 1). The prevalence of Black and Hispanic race/ethnicity tended to increase with higher BMI, whereas the prevalence of Asian/other and White race/ethnicity tended to decrease. Higher BMI was associated with lower median income but with a higher prevalence of commercial insurance (Table 1). Small but statistically significant differences in serum bicarbonate, SUN, and eGFR values were seen across BMI categories.

Association of BMI With Serum Bicarbonate

After multivariable adjustment, there was a J-shaped association of BMI with serum bicarbonate levels. Higher BMI above the normal range was associated with a graded decrease in serum bicarbonate levels, which was attenuated somewhat but remained significant with BMI ≥ 40 kg/m² (Fig 2A). Analyses using smaller BMI categories confirmed a graded association and suggested that higher BMI was associated with lower serum bicarbonate levels beginning with BMI ≥ 22.5 kg/m² and confirmed that at the highest BMI values, the association between BMI and serum bicarbonate levels begins to invert (Fig 2B).

Association of BMI With Serum Bicarbonate Over Time and With Incident Low Bicarbonate

During a median follow-up of 4.4 (interquartile range, 2.3–6.3) years, patients had a median of 8 (interquartile
Table 1. Baseline Characteristics by BMI Sextiles (World Health Organization Classification)

| Characteristic                  | BMI, kg/m\(^2\) | <18.5 | 18.5–<25 | 25–<30 | 30–<35 | 35–<40 | ≥40 | \(P\) |
|--------------------------------|------------------|-------|---------|-------|-------|-------|-----|-------|
| Patients                       |                  | 1,059 (1.1%) | 20,357 (21.2%) | 33,212 (34.5%) | 22,996 (23.9%) | 10,945 (11.4%) | 7,578 (7.9%) | <0.001 |
| Age, y                         |                  | 43.3 (22.8) | 48.7 (20.0) | 52.0 (16.5) | 51.4 (15.2) | 49.2 (14.6) | 45.5 (14.1) | <0.001 |
| Women                          |                  | 773 (73.0%) | 13,231 (65.0%) | 19,842 (59.7%) | 14,698 (63.9%) | 7,671 (70.1%) | 5,649 (74.5%) | <0.001 |
| Race/ethnicity                 |                  |          |         |       |       |       |     |       |
| Black                          |                  | 332 (31.3%) | 5,879 (28.9%) | 10,670 (32.1%) | 8,369 (36.4%) | 4,264 (39.0%) | 3,186 (42.0%) | <0.001 |
| Hispanic                       |                  | 320 (30.2%) | 6,687 (32.9%) | 12,106 (36.5%) | 8,535 (37.1%) | 3,965 (36.2%) | 2,722 (35.9%) | <0.001 |
| Asian/other race               |                  | 249 (23.5%) | 4,668 (22.9%) | 6,823 (19.9%) | 3,818 (16.6%) | 1,679 (15.3%) | 1,031 (13.8%) |          |
| White                          |                  | 158 (14.9%) | 3,123 (15.3%) | 3,813 (15.5%) | 2,274 (9.9%) | 1,037 (9.5%) | 639 (8.4%) |         |
| Median income by zip code      |                  |          |         |       |       |       |     |       |
| <$30,000                       |                  | 193 (18.2%) | 3,585 (17.6%) | 6,528 (19.7%) | 4,844 (21.1%) | 2,463 (22.5%) | 2,000 (26.4%) | <0.001 |
| $30,000–$49,999                |                  | 476 (45.0%) | 8,965 (44.0%) | 15,345 (46.2%) | 10,897 (47.4%) | 5,187 (47.4%) | 3,452 (45.6%) | <0.001 |
| $50,000–$69,999                |                  | 164 (15.5%) | 3,436 (16.9%) | 5,333 (16.1%) | 3,468 (15.1%) | 1,598 (14.6%) | 949 (12.5%) | <0.001 |
| ≥$70,000                       |                  | 84 (7.9%) | 1,710 (8.4%) | 2,344 (7.1%) | 1,416 (6.2%) | 635 (5.8%) | 374 (4.9%) | <0.001 |
| Not specified                  |                  | 142 (13.4%) | 2,661 (13.1%) | 3,662 (11.0%) | 2,371 (10.3%) | 1,062 (9.7%) | 803 (10.6%) | <0.001 |
| Baseline diagnoses             |                  |          |         |       |       |       |     |       |
| Hypertension                   |                  | 261 (24.6%) | 7,084 (34.8%) | 15,715 (47.3%) | 12,430 (54.1%) | 6,253 (57.1%) | 4,306 (56.8%) | <0.001 |
| Diabetes                       |                  | 90 (8.5%) | 3,236 (15.9%) | 7,872 (23.7%) | 6,989 (30.4%) | 3,761 (34.4%) | 2,745 (36.2%) | <0.001 |
| Coronary artery disease        |                  | 64 (6.0%) | 1,382 (6.8%) | 2,755 (8.3%) | 1,892 (8.2%) | 842 (7.7%) | 495 (6.5%) | <0.001 |
| Baseline laboratory values     |                  |          |         |       |       |       |     |       |
| eGFR,a mL/min/1.73 m\(^2\)    |                  | 101.3 (29.5) | 92.5 (25.6) | 88.4 (23.3) | 88.5 (23.3) | 90.9 (23.7) | 95.6 (23.9) | <0.001 |
| eGFR < 60 mL/min/1.73 m\(^2\) |                  | 98 (9.3%) | 2,106 (10.4%) | 3,642 (11.0%) | 2,476 (10.8%) | 1,030 (9.4%) | 552 (7.3%) | <0.001 |
| Serum bicarbonate,b mEq/L     |                  | 25.4 (2.6) | 25.6 (2.6) | 25.6 (2.5) | 25.5 (2.6) | 25.3 (2.6) | 26.4 (2.6) | <0.001 |
| Serum urea nitrogen,c mg/dL    |                  | 14.2 (6.0) | 14.8 (6.1) | 15.0 (5.6) | 14.9 (5.7) | 14.7 (5.8) | 14.2 (5.8) | <0.001 |

Note: Values expressed as number (percent) or continuous variables as mean (standard deviation). Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate.

*aCalculated using Chronic Kidney Disease Epidemiology Collaboration creatinine equation.

*bConversion to SI units (mmol/L): 1 mEq/L = 1 mmol/L.

*cConversion to SI units (mmol/L): 1 mg/dL = 0.357 mmol/L.
range, 5-13) serum bicarbonate measurements, and 34,539 (36%) developed low bicarbonate levels. Using time-updated BMI, eGFR, and serum bicarbonate values, the same J-shaped association was observed (Fig 2C and D), whereas the effect of time was significantly positive (0.01 mEq/L per 6-month period; \(P < 0.001\)). Higher BMI was associated with a progressively greater hazard of incident low bicarbonate levels through BMI of 40 kg/m\(^2\) (Fig 3A). Compared with patients with normal BMI, those with BMI of 35 to <40 kg/m\(^2\) had a 20% (95% CI, 14%-26%) higher hazard of developing low bicarbonate levels. This association was attenuated at higher BMI values but remained significant. When examined within smaller BMI categories, the same significant J-shaped relationship was observed (Fig 3B). Analysis using a restricted cubic spline model also revealed a J-shaped relationship (Fig S1).

**Effect Modification by Race/Ethnicity**

In prospective analyses, there was significant effect modification of the association of BMI with incident low bicarbonate levels by race/ethnicity (\(P < 0.01\)). At every BMI level, the hazard was greatest among White patients while nonsignificant among Black patients (Table 2). Among Hispanic and Asian/other patients, the hazard was significant but lower in magnitude compared with White patients (Table 2). These differences by race/ethnicity prompted further subgroup analysis to explore potential explanations for the effect modification. Given the association of diabetes with acid-base disturbances\(^{30}\) and the known differences in diabetes prevalence by race/ethnicity\(^{31}\), we repeated analyses in the subgroup of patients without baseline diabetes mellitus. In comparison to the whole cohort (Fig 3A and B), the association of higher BMI with higher hazard of low bicarbonate levels was similar (Fig 4). Among all subgroups analyzed, the largest magnitude of effect was seen among White patients without baseline diabetes (Fig S2a). As a comparison, among Black patients without baseline diabetes, the association of BMI with incident low bicarbonate levels was nonsignificant (Fig S2b).

**Sensitivity Analyses**

Including SUN level in our model attenuated slightly the degree to which higher BMI was associated with incident low bicarbonate levels but did not meaningfully change our results (Fig S3). When restricted to patients with eGFRs \(\geq 60\) mL/min/1.73 m\(^2\) (Fig S4), the increase in hazard of incident low bicarbonate level was greater in
magnitude compared with the combined cohort. The same occurred when analysis was limited to those without baseline hypertension (Fig S5). Analyses by eGFR subgroups revealed that associations of higher BMI with lower baseline serum bicarbonate levels and higher hazard of incident low bicarbonate levels were of greatest magnitude among patients with relatively preserved eGFRs (Fig S6; Table S1). Restricting the definition of incident low bicarbonate level to 2 low bicarbonate levels within 365 days or less of each other did not materially change the point estimates of hazard or the significance of the results (Table S2).

**DISCUSSION**

In a large diverse multiethnic cohort, we found that obesity is associated with lower serum bicarbonate levels and increased risk for developing low bicarbonate levels, an indicator of likely metabolic acidosis. Our results demonstrate graded associations of higher BMI with lower serum bicarbonate levels, even after adjustment for multiple potential confounders. Furthermore, among individuals without low bicarbonate levels at baseline, higher BMI was associated with a progressively greater risk for developing low bicarbonate levels. These associations increased in magnitude up to BMI of 40 kg/m², after

---

**Figure 3.** Association of body mass index (BMI) with incident low bicarbonate levels. (A, B) Hazard ratios according to (A) World Health Organization (WHO) BMI groups and (B) smaller BMI categories among participants without low bicarbonate levels at baseline. Models adjusted for age, sex, race/ethnicity, and baseline income, insurance status, estimated glomerular filtration rate, hypertension, diabetes, and coronary artery disease status. Bars denote 95% CI. n = 81,400; *P < 0.001; *P < 0.05. Abbreviation: ref, reference.

**Table 2.** The Hazard of Incident Low Bicarbonate by BMI Group, Subgroups by Race/Ethnicity

| BMI Group, kg/m² | Black Hazard Ratio | 95% CI | P  | Hispanic Hazard Ratio | 95% CI | P  |
|------------------|--------------------|-------|----|----------------------|-------|----|
| 18.5<25          | Reference          | 0     |    | Reference            | 0     |    |
| 25<30            | 1.02               | 0.94-1.09 | 0.66 | 1.10               | 1.03-1.18 | 0.01 |
| 30<35            | 1.06               | 0.98-1.14 | 0.14 | 1.17               | 1.09-1.26 | <0.001 |
| 35<40            | 1.08               | 0.99-1.18 | 0.08 | 1.22               | 1.12-1.33 | <0.001 |
| >40              | 1.04               | 0.94-1.14 | 0.49 | 1.21               | 1.09-1.34 | <0.001 |

| BMI Group, kg/m² | Asian/Other Hazard Ratio | 95% CI | P  | White Hazard Ratio | 95% CI | P  |
|------------------|--------------------------|-------|----|--------------------|-------|----|
| 18.5<25          | Reference                | 0     |    | Reference          | 0     |    |
| 25<30            | 1.15                     | 1.05-1.26 | <0.01 | 1.21               | 1.08-1.36 | <0.01 |
| 30<35            | 1.18                     | 1.06-1.30 | <0.01 | 1.38               | 1.21-1.57 | <0.001 |
| 35<40            | 1.26                     | 1.11-1.43 | <0.001 | 1.41               | 1.20-1.66 | <0.001 |
| >40              | 1.15                     | 0.98-1.34 | 0.08 | 1.38               | 1.14-1.67 | <0.01 |

Abbreviations: BMI, body mass index.
which they were attenuated but remained significant. These findings persisted even after excluding individuals with diabetes or CKD. Overall, our results indicate that obesity is a previously unrecognized risk factor for the development of low bicarbonate levels in a non-CKD population.

Given that greater BMI and waist circumference have been associated with higher PCO2 levels, it is unlikely that lower serum bicarbonate levels among obese individuals on a population level is a result of renal compensation for hyperventilation-induced respiratory alkalosis. Therefore, these results likely represent metabolic acidosis. Prior research demonstrates an association of greater obesity with impaired renal acid excretion, including lower urinary pH. More metabolic syndrome features, and specifically greater insulin resistance, are also associated with progressively lower urinary pH, implicating a causal role for obesity-related metabolic dysfunction.

A recent study has also shown a positive association of BMI and net acid excretion rates that is independent of diet, and that obese individuals excrete a lower proportion of total urinary acid as ammonium. Thus, obese individuals may have elevated acid generation rates in addition to an impaired capacity to excrete the daily acid load. Over time, resultant net acid retention would be expected to deplete body buffers, with a reduction in serum bicarbonate levels a relatively late effect. Our results now support the idea that this acid retention is proportional to excess weight and also incompletely compensated. Although our study was not designed to examine whether metabolic acidosis contributes to CKD development in the obese, our results now link obesity to a well-known risk factor for CKD development.

We suspect that the J-shaped relationship in our results likely reflects the presence of undiagnosed obesity hyperventilation syndrome at higher BMI values. The inflection points observed in our analyses occurred at BMI values between 40 and 45 kg/m², consistent with the average BMI among patients with diagnosed obesity hyperventilation syndrome. However, prior research has shown that obesity-related carbon dioxide retention is not limited to morbid obesity but rather occurs in lesser stages of obesity. For this reason, our results likely underestimate the true magnitude of acid-base disturbance among individuals with greater degrees of obesity.

The near absence of a relationship between BMI and bicarbonate levels in Black patients was especially striking. Prior research has shown that postmenopausal Black women compared with White women have significantly higher urinary pH that is independent of dietary intake and other urinary markers. Skin fibroblasts in Black compared with White patients have higher sodium-hydrogen antiporter activity, suggesting possible differences in the kinetics of acid-base homeostatic mechanisms. Alternatively, BMI compared with other markers has been shown to be a poor predictor of metabolic risk in Black women, which may limit its utility as a predictor of outcomes in our study.

The near absence of an association of BMI with serum bicarbonate levels or incident low bicarbonate levels among those with lower eGFRs (Fig S6; Table S2) may be due to undocumented use among this subgroup of diuretics or alkali. Additionally, because declining GFR is a significant risk factor for metabolic acidosis, the risk for low bicarbonate levels attributable to BMI at lower GFRs may be more difficult to detect. Although the wide CIs make it difficult to draw conclusions about the association of BMI and baseline bicarbonate levels among patients with eGFRs of 15 to <30 mL/min/1.73 m², these results suggest a positive rather than negative association in this subgroup (Fig S6). Discordant with this is the suggestion of a still elevated risk for incident low bicarbonate levels among obese class II patients in this subgroup in the survival analysis (Table S4). These results again may be due to alkali and diuretic treatment, which may raise the average bicarbonate levels among these groups, but not completely mitigate the risk for incident low bicarbonate levels. Further investigation is warranted in larger CKD cohorts.

Limitations of our study relate to the observational study design. In this large cohort, we were unable to confirm acid-base status because of the lack of arterial blood gases. Future studies should confirm our findings with arterial pH measurements. Measurements of bicarbonate are subject to daily fluctuations from diet and variations due to sample handling, effects that we would expect to bias our results toward the null hypothesis. There is also the possibility that differences in dietary alkali or protein intake related to obesity could partly explain our findings; we were also unable to control for the effect of

Figure 4. Association of body mass index (BMI) with serum bicarbonate levels among participants without diabetes. Differences in baseline serum bicarbonate levels according to World Health Organization (WHO) BMI groups among patients without baseline diabetes mellitus. Model adjusted for age, sex, race/ethnicity, and baseline income, insurance status, estimated glomerular filtration rate, hypertension, and coronary artery disease status. Bars denote 95% CI. n = 71,454; *P < 0.001.
dietary net endogenous acid production on serum bicarbonate levels\textsuperscript{14} and were limited to using SUN level as a surrogate for dietary protein. Finally, we were unable to definitively exclude from our analysis patients with undocumented obesity hypoventilation syndrome, whose inclusion may have confounded our results toward an underestimation of the degree of low bicarbonate levels in those with obesity.

If confirmed by future studies, our findings suggest that weight loss and measures to reduce acid production, such as increased consumption of fruits and vegetables,\textsuperscript{18,45} may be important population-level interventions to reduce risk factors for CKD development and mortality in those with overweight and obesity.

**SUPPLEMENTARY MATERIAL**

**Supplementary File (PDF)**

- **Figure S1:** Restricted Cubic Spline Model of Association of BMI With Incident Low Bicarbonate.
- **Figure S2:** Association of BMI With Incident Low Bicarbonate Among Patients Without Diabetes.
- **Figure S3:** Association of BMI With Incident Low Bicarbonate After Adjustment for Serum Urea Nitrogen.
- **Figure S4:** Association of BMI With Incident Low Bicarbonate Among Patients With an Estimated Glomerular Filtration Rate (eGFR) $\geq 60$ mL/min/1.73 m$^2$.
- **Figure S5:** Association of BMI With Incident Low Bicarbonate Among Patients Without Hypertension.
- **Figure S6:** Association of BMI With Serum Bicarbonate Levels Among Estimated Glomerular Filtration Rate (eGFR) Subgroups.
- **Table S1:** Association of BMI With Incident Low Bicarbonate Among Estimated Glomerular Filtration Rate (eGFR) Subgroups.
- **Table S2:** Effect of Low Bicarbonate Definition on Association of BMI With Incident Low Bicarbonate.

**ARTICLE INFORMATION**

**Authors’ Full Names and Academic Degrees:** Douglas C. Lambert, MD, and Matthew K. Abramowitz, MD, MS.

**Authors’ Affiliations:** Department of General Internal Medicine (DCL) and Division of Obesity Medicine (DCL), Northwell Health, Great Neck; and Department of Medicine (MKA), Institute for Aging Research (MKA), Diabetes Research Center (MKA), and Fleisher Institute for Diabetes and Metabolism (MKA), Albert Einstein College of Medicine, Bronx, NY.

**Address for Correspondence:** Douglas C. Lambert, Department of General Internal Medicine, Northwell Health, Irving Goldman Family Care Center, 865 Northern Blvd, Ste 102, Great Neck, NY 11021. Email: dlambert1@northwell.edu

**Authors’ Contributions:** Research idea and study design: DCL, MKA; data acquisition: DCL; data analysis and interpretation: DCL, MKA; statistical analysis: DCL, MKA: supervision or mentorship: MKA. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

**Support:** Dr Abramowitz was supported by K23DK099438 from the National Institutes of Health.

**Financial Disclosure:** Dr Abramowitz has received consulting fees from Tricida, Inc. Dr Lambert declares that he has no relevant financial interests.

**Prior Presentation:** Data from this project were presented as an online poster abstract at the Society of General Internal Medicine 2020, May 6-9, 2020, virtual meeting.

**Peer Review:** Received July 10, 2020. Evaluated by 2 external peer reviewers, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form February 15, 2021.

**REFERENCES**

1. Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol. 2009;20(1):164-171.
2. Garibotto G, Russo R, Sofia A, et al. Muscle protein turnover in chronic renal failure patients with metabolic acidosis or normal acid-base balance. Miner Electrolyte Metab. 1996;22(1-3):58-61.
3. Abramowitz MK, Hostetter TH, Melamed ML. Association of serum bicarbonate levels with gait speed and quadriceps strength in older adults. Am J Kidney Dis. 2011;58(1):29-38.
4. Yenchek R, Jr JH, Rifkin DE, et al. Association of serum bicarbonate with incident functional limitation in older adults. Clin J Am Soc Nephrol. 2014;9(12):2111-2116.
5. Kraut JA, Mishler DR, Singer FR, Goodman WG. The effects of metabolic acidosis on bone formation and bone resorption in the rat. Kidney Int. 1986;30(5):694-700.
6. Raphael KL, Wei G, Baird BC, Greene T, Bedhu S. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int. 2011;78(3):356-362.
7. Kovessy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant. 2009;24(4):1232-1237.
8. Raphael KL, Murphy RA, Shlipak MG, et al. Bicarbonate concentration, acid-base status, and mortality in the Health, Aging, and Body Composition Study. Clin J Am Soc Nephrol. 2016;11(2):308-316.
9. Wesson DE, Mathur V, Tangri N, et al. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet. 2019;394(10196):396-406.
10. Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int. 2010;78(3):303-309.
11. Di Iorio BR, Bellasi A, Raphael KL, et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol. 2019;32(6):989-1001.
12. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20(9):2075-2084.
13. Driver TH, Shlipak MG, Katz R, et al. Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2014;64(4):534-541.
14. Abramowitz MK, Hostetter TH, Melamed ML. Lower serum bicarbonate and a higher anion gap are associated with lower
cardiorespiratory fitness in young adults. Kidney Int. 2012;81(10):1033-1042.

15. Mandel EI, Curhan GC, Hu FB, Taylor EN. Plasma bicarbonate and risk of type 2 diabetes mellitus. CMAJ. 2012;184(13):E719-E725.

16. Chen W, Melamed ML, Abramowitz MK. Serum bicarbonate and bone mineral density in US adults. Am J Kidney Dis. 2015;65(2):240-248.

17. Goraya N, Simoni J, Jo CH, Wesson DE. Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. Kidney Int. 2014;86(5):1031-1038.

18. Goraya N, Simoni J, Jo C, Wesson DE. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int. 2012;81(1):86-93.

19. Frassetto L, Morris RC Jr, Sebastian A. Potassium bicarbonate reduces urinary nitrogen excretion in postmenopausal women. J Clin Endocrinol Metab. 1997;82(1):254-259.

20. Sebastian A, Harris ST, Ottaway JH, Todd KM, Morris RC Jr. Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N Engl J Med. 1994;330(25):1776-1781.

21. Jehle S, Hulter HN, Krapf R. Effect of potassium citrate on bone density, microarchitecture, and fracture risk in healthy older adults without osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2013;98(1):207-217.

22. Raphael KL, Zhang Y, Ying J, Greene T. Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease. Nephrology (Carlton). 2019;14(3):411-420.

23. Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis. 2006;48(6):905-915.

24. Bobulescu IA, Park SK, Xu LHR, et al. Net acid excretion and urinary organic anions in idiopathic uric acid nephrolithiasis. Clin J Am Soc Nephrol. 2019;14(3):411-420.

25. Xu H, Kuja-Halkola R, Chen X, Magnusson PKE, Svensson P, Carrero JJ. Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding. Kidney Int. 2019;95(5):1225-1233.

26. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364-2373.

27. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523-1529.

28. United States Census Bureau. 2013-2017 ACS 5-year estimates. Vol 2018. Accessed December 12, 2019. https://www.census.gov/topics/income-poverty/income/data/tables/acs.html

29. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.

30. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988;37(8):1020-1024.

31. Golden SH, Brown A, Cauley JA, et al. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors—an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2012;97(9):E1579-E1639.

32. Gabrielsen AM, Lund MB, Kongerud J, Viken KE, Roislien J, Hjelmesaeth J. The relationship between anthropometric measures, blood gases, and lung function in morbidly obese white subjects. Obes Surg. 2011;21(4):485-491.

33. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422-1425.

34. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386-392.

35. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2(5):883-888.

36. Wesson DE, Simoni J, Broglio K, Sheather S. Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. Am J Physiol Renal Physiol. 2011;300(4):F830-F837.

37. Mokhlesi B, Tuliamt A, Faibussowitsch I, Wang Y, Evans AT. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath. 2007;11(2):117-124.

38. Macavei VM, Spurling KJ, Loft J, Makker HK. Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med. 2013;9(9):879-884.

39. Taylor EN, Curhan GC. Differences in 24-hour urine composition between black and white women. J Am Soc Nephrol. 2007;18(2):654-659.

40. Hatori N, Gardner JP, Tomonari H, Fine BP, Avi A, Na(+)-H+ antiport activity in skin fibroblasts from blacks and whites. Hypertension. 1990;15(2):140-145.

41. Allister-Price C, Craig CM, Spielman D, Cushman SS, McLaughlin TL. Metabolic markers, regional adiposity, and adipose cell size: relationship to insulin resistance in African-American as compared with Caucasian women. Int J Obes (Lond). 2019;43(6):1164-1173.

42. Rune SJ. Comparison of the rates of gastric acid secretion in man after ingestion of food and after maximal stimulation with histamine. Gut. 1966;7(4):344-350.

43. Laski ME. Penny wise and bicarbonate foolish. Am J Kidney Dis. 2000;35(6):1224-1225.

44. Amodu A, Abramowitz MK. Dietary acid, age, and serum bicarbonate levels among adults in the United States. Clin J Am Soc Nephrol. 2013;8(12):2034-2042.

45. Goraya N, Munoz-Maldonado Y, Simoni J, Wesson DE. Fruit and vegetable treatment of chronic kidney disease-related metabolic acidosis reduces cardiovascular risk better than sodium bicarbonate. Am J Nephrol. 2019;49(6):438-448.
Conclusion: A higher BMI is independently associated with a progressively greater risk for developing a low serum bicarbonate, indicating likely metabolic acidosis.

Reference: Lambert DC, Abramowitz MK. Obesity and the risk of low bicarbonate: a cohort study. Kidney Medicine, 2021.

Visual Abstract by Denisse Arellano, MD
@denisse_am